Innoviva's CEO expressed confidence in the company's near-term commercial momentum and long-term strategy, including expansion into new therapeutic areas and key product launches like Nuzolvence. The firm maintains an $18 price target, citing resilience in the royalty business and strong execution in IST.
Key Takeaways
- 1.The CEO expressed confidence in business trends, highlighting resilience in the royalty business with ~2/3 of revenue from OUS.
- 2.Innoviva intends to expand beyond infectious disease into new therapeutic areas using current infrastructure and commercial relationships.
- 3.The company remains on track for the 2H26 launch of Nuzolvence, positioning it as an alternative to injectables.
Table of Contents
- Presenters: Pavel Raifeld, CEO
- Valuation/Risks
- Valuation
- Upside risks
- Disclosure Appendix
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Company-specific regulatory disclosures
- Distribution of ratings/investment banking relationships
- Price target and rating history chart(s)
- Regulatory disclosures
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Asad Haider, CFANick JenningsJeff Su
Securities
INVA
Themes
Healthcare Strategic ExpansionRoyalty Revenue Resilience
Regions
GlobalUnited States